Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors

Chronic lymphocytic leukemia (CLL) shows a remarkable heterogeneity, with some patients having an almost normal lifespan, others surviving only several months after diagnosis despite intensive therapy. The aim of this study was to investigate the serum thymidine kinase 1 (TK1) concentration in Chinese patients with CLL and its correlation with well-established other prognostic factors. Enhanced chemiluminescent dot blot assay was performed to measure serum TK1 concentration in 80 CLL patients. The concentration of TK1 was significantly increased in patients with Binet C (P = 0.002), higher levels of serum lactate dehydrogenase (LDH) (P = 0.012) and β2-microglobulin (β2-MG) (P = 0.025), unmutated IGHV status (P < 0.001), or higher expression levels of ZAP-70 (P = 0.014) and CD38 (P = 0.018) groups compared to the patients with Binet A, lower levels of serum LDH and β2-MG, mutated IGHV status, or lower expression levels of ZAP-70 and CD38 groups, respectively. Strong correlation of TK1 level with IGHV mutations (r = 0.412, P < 0.001) or ZAP-70 (r = 0.263, P = 0.024) was observed. According to receiver operating characteristic curve analysis for serum TK1 concentration and IGHV mutational status, area under the curve was 0.757 (P = 0.001) and the optimal cut-off value of serum TK1 concentration level was 1.75 pM, with a 87.8% specificity, a 63.6% sensitivity. It was showed that serum TK1 concentration could be a predictive marker of IGHV mutational status, and might be applied for the assessment of prognosis in patients with CLL.

[1]  B. Emmerich,et al.  Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications , 1992, Annals of Hematology.

[2]  H. Johansson,et al.  Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. , 2006, Anticancer research.

[3]  M. Hallek,et al.  Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. , 1996, Leukemia & lymphoma.

[4]  P. Gobbi,et al.  Serum thymidine kinase in monoclonal gammopathies. A prospective study , 1992, Cancer.

[5]  Jian-yong Li,et al.  Cytogenetic characterisation in Chinese patients with chronic lymphocytic leukemia: A prospective, multicenter study on 143 cases analysed with interphase fluorescence in situ hybridisation , 2008, Leukemia & lymphoma.

[6]  Mark J. Thomas,et al.  A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis , 1981, Cancer.

[7]  T. Kelly,et al.  Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis , 1991, Molecular and cellular biology.

[8]  R. Porcher,et al.  Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL , 2003, Leukemia.

[9]  Jian-yong Li,et al.  CD38 as a prognostic factor in Chinese patients with chronic lymphocytic leukaemia. , 2009, Leukemia research.

[10]  S. Tucker,et al.  Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase. , 1995, Leukemia & lymphoma.

[11]  B Simonsson,et al.  Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia , 1984, Cancer.

[12]  M. Grever,et al.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.

[13]  Z. Chang,et al.  Mitotic Degradation of Human Thymidine Kinase 1 Is Dependent on the Anaphase-Promoting Complex/Cyclosome-Cdh1-Mediated Pathway , 2004, Molecular and Cellular Biology.

[14]  K. Nilsson,et al.  Serum deoxythymidine kinase correlates with peripheral lymphocyte thymidine uptake in chronic lymphocytic leukemia , 1987, European journal of haematology.

[15]  Xiuqin Wang,et al.  Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity. , 2005, Oncology reports.

[16]  W. Xu,et al.  Distinctive IgVH gene segments usage and mutation status in Chinese patients with chronic lymphocytic leukemia. , 2008, Leukemia research.

[17]  S. Eriksson,et al.  Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. , 1996, European journal of cell biology.

[18]  E. Cronkite,et al.  Clinical staging of chronic lymphocytic leukemia. , 1975, Blood.

[19]  E. Thiel,et al.  Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. , 1999, Blood.